- Home
- ADAG vs IKNA Comparison
ADAG vs IKNA Comparison
Compare ADAG & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAG
- IKNA
- Stock Information
- Founded
- ADAG 2011
- IKNA 2016
- Country
- ADAG China
- IKNA United States
- Employees
- ADAG N/A
- IKNA N/A
- Industry
- ADAG Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- ADAG Health Care
- IKNA Health Care
- Exchange
- ADAG Nasdaq
- IKNA Nasdaq
- Market Cap
- ADAG 91.4M
- IKNA 63.7M
- IPO Year
- ADAG 2021
- IKNA 2021
- Fundamental
- Price
- ADAG $1.92
- IKNA $1.36
- Analyst Decision
- ADAG Strong Buy
- IKNA Strong Buy
- Analyst Count
- ADAG 1
- IKNA 1
- Target Price
- ADAG $8.00
- IKNA $4.00
- AVG Volume (30 Days)
- ADAG 51.2K
- IKNA 60.0K
- Earning Date
- ADAG 07-24-2025
- IKNA 08-07-2025
- Dividend Yield
- ADAG N/A
- IKNA N/A
- EPS Growth
- ADAG N/A
- IKNA N/A
- EPS
- ADAG N/A
- IKNA N/A
- Revenue
- ADAG $103,204.00
- IKNA N/A
- Revenue This Year
- ADAG $6,488.89
- IKNA N/A
- Revenue Next Year
- ADAG $57.50
- IKNA N/A
- P/E Ratio
- ADAG N/A
- IKNA N/A
- Revenue Growth
- ADAG N/A
- IKNA N/A
- 52 Week Low
- ADAG $1.33
- IKNA $0.97
- 52 Week High
- ADAG $3.58
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- ADAG 56.78
- IKNA 53.81
- Support Level
- ADAG $1.74
- IKNA $1.31
- Resistance Level
- ADAG $1.98
- IKNA $1.42
- Average True Range (ATR)
- ADAG 0.12
- IKNA 0.05
- MACD
- ADAG -0.00
- IKNA -0.00
- Stochastic Oscillator
- ADAG 72.22
- IKNA 45.45
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.